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Abstract
The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated
by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma
(UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains
whether UTUC and the subsequent UCB are clonally related or represent separate
origins. To investigate the clonal relationship between both entities, we performed
targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tis-
sue of 15 primary UTUC patients treated by RNU who later developed 19 UCBs.
Based on the detected tumor-specific DNA aberrations, the paired UTUC and UCB(s)
of 11 patients (73.3%) showed a clonal relation, whereas in four patients the molecu-
lar results did not indicate a clear clonal relationship. Our results support the hypoth-
esis that UCBs following a primary surgically resected UTUC are predominantly
clonally derived recurrences and not separate entities.
Abbreviations: AI, allelic imbalance; Indels, insertion/deletion; LS, Lynch syndrome; NGS, next-generation sequencing; SNP, single-nucleotide polymorphism; SNV, single-nucleotide variants;
TCGA, The Cancer Genome Atlas; UCB, urothelial carcinoma of the bladder; UTUC, upper urinary tract urothelial carcinoma; VAF, variant allelic frequency.
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1 | INTRODUCTION
Patients undergoing radical nephroureterectomy (RNU) for upper uri-
nary tract urothelial carcinoma (UTUC) have 22% to 47% risk of devel-
oping a subsequent urothelial carcinoma of the bladder (UCB) within
2 years.1 Two hypotheses have been proposed for this increased risk.
Firstly, the entire urinary tract of patients with urothelial carcinoma
undergoes a “field change,” priming the tissue for independent trans-
formations.2 Upper and lower tract tumors therefore develop inde-
pendently from one another and are not clonally related. Secondly, by
intraluminal seeding or intraepithelial spread, cancer cells from the pri-
mary UTUC implant in the bladder wall and develop into a UCB
resulting in clonally related tumors.3 Recently, we performed a sys-
tematic review of the literature on the clonal relationship between
UTUC and paired UCB and found that 94% of the cases originated
from the same progenitor cell.4 However, the molecular techniques
used differed largely over time and research groups, plus only a lim-
ited number of studies used comprehensive large-scale DNA sequenc-
ing techniques, which enables more conclusive assessment of a clonal
relation between these two entities.
In our study, we used targeted DNA next-generation sequencing
(NGS) to analyze the clonal relationship of primary UTUC and subse-
quent UCB in patients treated with an RNU based on shared genomic
alterations.
2 | MATERIALS AND METHODS
2.1 | DNA extraction
Tumor hematoxylin and eosin slides were reviewed by an expert geni-
tourinary pathologist (GvL) and regions containing ≥50% tumor cells
were selected for DNA isolation (Supplementary Table 2). Tumor and
corresponding normal tissue sections were manually microdissected in
5% Chelex 100 Resin (Bio-Rad, Hercules, CA) cell lysis solution
(Promega, Madison, WI). DNA was extracted by proteinase K (Roche,
Mannheim, Germany) digestion at 56C. Proteinase K was inactivated
for 10 minutes at 95C after which the samples were centrifuged for
5 minutes at 14000 rpm to collect cell debris and chelexresin. Finally,
DNA was collected into new tubes and the concentration was mea-
sured by using a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Wal-
tham, MA), as described by the manufacturer.
2.2 | Next-generation targeted sequencing
For targeted NGS, a custom-made cancer panel was designed using
the AmpliSeq designer (Thermo Fisher Scientific, Waltham, MA). This
panel comprised 330 amplicons covering 41 genes, multiple hotspot
regions in various cancer-related genes and 154 single nucleotide
polymorphisms in multiple tumor suppressor regions to detect copy
number variations (Table 2 and Supplementary Table 3).5-7 NGS was
performed with the Ion Torrent platform using supplier's materials
and protocols (Thermo Fisher Scientific). Median coverage depths
were 1994x for UTUC, 1712x for UCB and 1914x for the adjacent
normal tissue. Libraries were made using the Ion AmpliSeq Library Kit
plus–384 LV, template was prepared with the Ion 510/520/530 Chef
kit and sequencing was performed on a 530-chip using the Ion S5 sys-
tem. Data were analyzed using SeqPilot (JSI medical systems). To cor-
rect for potential germline mutations, NGS was also performed on
DNA isolated from matched nonmalignant kidney tissue. The final
tumor cell percentage was calculated based on the DNA quality and
quantity and the results of the NGS.
2.3 | Genomic alterations
A visual inspection by an experienced technician (ICM) and clinical sci-
entist (HJD) in molecular pathology making use of Torrent Variant Cal-
ler and SNPitty was carried out to identify the genomic alterations.6
These genomic alterations were stored in VCF format.6,8 Figure 1
summarizes all detected genomic alterations; single-nucleotide vari-
ants (SNVs), indels, allelic imbalance (AI), amplifications and homozy-
gous deletions. For AI analysis, single nucleotide polymorphisms with
a total coverage of >100 reads were included. For any informative
SNP without AI, a variant allele frequency (VAF) of 0.5 was expected.
With a VAF of <0.5 (relative loss of variant allele) or a VAF of >0.5
(relative loss of reference allele), AI was indicated.9
What's new?
Patients treated by radical nephroureterectomy for upper
urinary tract cancer have an increased risk of developing
bladder carcinoma following surgery. It remains unclear,
however, whether the upper urinary tract cancer and subse-
quent bladder carcinoma are clonally related or have sepa-
rate origins. This targeted DNA sequencing study shows that
almost 75% of patients have tumors that are clonally related,
suggesting that seeding of tumor cells is the main mechanism
of bladder carcinoma development following radical neph-
roureterectomy. This result underscores the need to min-
imalize the risk of seeding during surgery and/or diagnostic
ureterorenoscopy plus biopsy, and to apply peri-operative
intravesical instillations with chemotherapy.
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TABLE 1 Patient, treatment and tumor characteristics of 15 patients diagnosed with a primary upper urinary tract urothelial carcinoma and a
subsequent urothelial carcinoma of the bladder
Variable Variable
Patient characteristics, n = 15
Male sex—no. (%) 8 (53.3%) Smoking status
Age, years, median (IQR) 67 (12.5) Never 3 (20.0%)
Former 9 (60.0%)
Current 3 (20.0%)
Treatment characteristics, n = 15
Preoperative URS—no. (%) 10 (66.7%) Hospital that performed RNU—no. (%)
Bladder cuff removal—no. (%) 10 (66.7%) Erasmus Medical Center, Rotterdam 7 (46.7%)
Perioperative systemic chemotherapy—no. (%) 0 (0.0%) Netherlands Cancer Institute, Amsterdam 7 (46.7%)
Perioperative intravesical instillation with
chemotherapy—no. (%)
2 (13.3%) Radboud University Center, Nijmegen 1 (6.6%)
UTUC characteristics, n = 15
Lateralization—no. (%)
Left 7 (46.7%)
Right 8 (53.3%)
Localization—no. (%)
Renal pelvis 9 (60.0%)
Ureter 6 (40.0%)
Pathological T-stage—no. (%)
pTa 9 (60.0%)
pT1 1 (6.7%)
pT2 3 (20.0%)
pT3 2 (13.3%)
Tumor grade (WHO 1973)—no. (%)
Grade 1 1 (6.7%)
Grade 2 9 (60.0%)
Grade 3 5 (33.3%)
Tumor grade (WHO 2004/2016)—no. (%)
Low grade 5 (33.3%)
High grade 10 (66.7%)
Pathological N-stage—no. (%)
pNx 14 (93.3%)
pN0 1 (6.7%)
UCB characteristics, n = 19 Time to UCB (months), median (IQR) 16.0 (11.5)
Pathological T-stage—no. (%)
pTis 2 (10.5%)
pTa 15 (79.0%)
pT1 2 (10.5%)
Tumor grade (WHO 1973)—no. (%)
Grade 1 2 (10.5%)
Grade 2 10 (52.6%)
Grade 3 7 (36.8%)
Tumor grade (WHO 2004/2016)—no. (%)
Low grade 8 (42.1%)
High grade 11 (57.9%)
Abbreviations: IQR, interquartile range; RNU, radical nephroureterectomy; TNM stage, based on seventh TNM classification of malignant tumors; UCB,
urothelial carcinoma of the bladder; URS, ureterorenoscopy; UTUC, upper urinary tract urothelial carcinoma.
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2.4 | Clonality assessment
A possible clonal relationship between UTUC and subsequent UCB(s) was
assessed by interrogating all SNVs including synonymous mutations,
amplifications, indels and supportive information on AI. To identify if a
mutation that was reported in one sample but not in the paired other
sample because of insufficient quality reads or absence of that mutation,
the following steps were undertaken. A list of all mutations reported in
TABLE 2 Genes included in the next-
generation DNA targeted sequencing
panel
Gene Exons covered Gene or region Numbers of SNPs included
CDKN2A Chr1p 11 SNPs
PTEN Chr8p 9 SNPs
TP53 Chr7 9 SNPs
AKT1 Exon 3 Chr19q 9 SNPs
ALK Exons 20, 22-25 APC 9 SNPs
Amel_X Not applicable ARID1A 8 SNPS
Amel_Y Not applicable ATM 9 SNPs
APC Exon 14 BRCA1 9 SNPs
ARAF Exon 7 BRCA2 9 SNPs
BRAF Exons 11, 15 CDKN2A 9 SNPs
CHEK2 Exons 4, 5, 12, 13 FHIT 9 SNPs
CTNNB1 Exons 3, 7, 8 PTEN 9 SNPs
EGFR Exons 18-21 RB1 9 SNPs
ERBB2 Exons 19-21 SMAD4 9 SNPs
EXH2 Exon 16 STK11 9 SNPs
FBXW7 Exons 9, 10 TP53 9 SNPs
FGFR1 Exons 7, 9 VHL 9 SNPs
FGFR2 Exons 7, 9
FGFR3 Exons 7, 9
FOXL2 Exon 3
GNA11 Exons 4,5 Total number of amplicons
GNAS Exons 8, 9 330
HRAS Exons 2–4
IDH1 Exon 4
IDH2 Exon 4
KIT Exons 8, 9, 11, 13, 14, 17
KRAS Exons 2–4
MAP2K1 Exons 2, 3
MET Exons 2, 14, 19
MYD88 Exon 5
NOTCH1 Exons 26, 27
NRAS Exons 2–4
PDGFRa Exons 12, 14, 18
PIK3CA Exons 10, 21
POLD1 Exons 12
POLE Exons 9, 13
RAF1 Exon 7
RET Exons 11, 16
RNF43 Exons 3, 4, 9
SMAD4 Exons 3, 9, 12
STK11 Exons 4, 5, 8
TERT promoter Promoter region
Note: Diagnostic V5.1 next-generation sequencing panel. Erasmus Medical Center, Rotterdam.
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one patient (UTUC and UCBs) was gathered. For every specific position,
reads for normal and tumor samples (Phred quality score above ≥15) were
subtracted from the BAM files using the bam2R function from the
deepSNV (v1.30.0) R package.10 Only sites where all samples (tumor and
normal) reported a minimum total reads of 30x were included for clonality
analysis. The total number of reads was the sum of reference reads plus
alternative reads. The VAF from normal tissue samples (VAFN) was used
as reference to determine SNVs. SNVs and indels were identified when
VAFN < 0.10 and VAFT > 0.10. Three samples, the UCBs from Patients II,
V and VI, showed some degree of DNA degradation, and the VAFT
F IGURE 1 Assessment of the clonal relation of 15 primary UTUC and 19 subsequent UCBs based on (non)shared tumor-specific genomic
alterations between both entities detected by next-generation sequencing. Additional transcriptomic profiling based on mRNAseq data is
included for patients X, XI, XII and XIV (NU, normal ureteric tissue; UCB, urothelial carcinoma of the bladder; UTUC, upper urinary tract urothelial
carcinoma) [Color figure can be viewed at wileyonlinelibrary.com]
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threshold value was increased to 0.30 to discard most of the false posi-
tives with very low VAFT.
The probability of a clonal relationship between UTUC and UCB
samples from the same patient was evaluated following the clonality
test approach developed by Ostrovnaya et al.11 The test was per-
formed on all SNVs and indels. As described by Mauguen et al, the
clonality test based on SNVs and indels was performed using the
mutation reference data set for bladder cancer from the TCGA
study.12 More specifically, frequencies of specific SNVs are assumed
to be known. The frequency f = x/n, where x is the number of tumors
with a specific SNV and n is the total number of tumors based on
n = 411 bladder cancer tumors from the TCGA cohort. Note that
hotspot mutations would have high frequencies and rare mutations
would have very low frequencies. When mutations have not been
reported in the TCGA data set (in case of indels and rare SNVs), the
frequency of these mutations was estimated as f = m/(n + m), where
m is the number of patients carrying that specific SNV or indel. The
frequencies of hotspot mutations in TERT promoter (pTERT) have not
been included in the TCGA data set. We completed the data set by
adding reported frequencies of pTERT C228T (64%) and C250T (13%)
mutations from a study by Allory et al.13 Based on the marginal fre-
quency of all SNVs and indels, the likelihood ratio test was applied to
estimate the probability of a clonal origin of the paired UTUC and
UCB.11 P values were adjusted with the Benjamin and Hochberg
method and adjusted P values <.05 were considered significant.
3 | RESULTS
In total, 15 patients with primary UTUC, treated by RNU, who subse-
quently developed 19 UCBs, treated by transurethral resection of the
bladder, were included. Patient, treatment and tumor characteristics of
the study population are listed in Table 1 and Supplementary Table 1.
Shared genomic variants revealed that UTUC and paired UCB(s) were
clonally related in 11 of 15 patients (73.3%) (Figure 1). No significance
(PAdj = .086) was found for the single-shared TERT (C250T) mutation in
Patient IV; however, comparable AI patterns supported clonal origin.
Patient XIII, diagnosed with Lynch syndrome (LS), only shared a Fibro-
blast Growth Factor Receptor (FGFR)-3 mutation (p.R248C; c.742C>T)
between both tumors. However, as this mutation only occurs in less
than 1% of urothelial carcinoma, a clonal relationship remained statisti-
cally significant (PAdj = .025). Patients II and XV also exhibited only a
single-shared mutation between both tumors, but as these alterations
are common hotspot mutations in urothelial carcinoma, the presence in
both entities did not unambiguously reflect a clonal relation. In Patients
I and VI, we did not observe any shared somatic mutations, so could not
support a clonal relationship.
4 | DISCUSSION
Studies that used large-scale sequencing techniques to assess the
clonality of UTUC and paired UCB are scarce. In 2017, Du et al
analyzed five patients with synchronous UTUCs (n = 9) and UCBs
(n = 4) by whole exome sequencing.14 Tumors were clonally related in
only two patients; a lower proportion than we found in the present
study. Exposure to aristocholic acid was linked to tumor development
in all five patients, which possibly affected the entire urothelium lead-
ing to field cancerization. Audenet et al reported on a cohort of
29 patients with paired UTUC and UCB, and found all tumors to be
clonally related, although this cohort also included patients with a his-
tory of primary UCB and some exhibited synchronous tumors.15 In
the present study, we only included patients with primary UTUC and
metachronous UCB(s); an approach which more accurately reflects
the natural course of surgically treated UTUC patients.
The observed differences in cohort clonality may reflect patient
idiosyncrasies, but also highlight remaining technical challenges.
Targeted panels do not to cover all genomic aberrations, so clonality
might have been underestimated in our study. Shared alterations
could have been missed due to the extent of this panel, which
increases the likelihood that the UCBs, which were found not to be
clonally related, could have been clonally derived recurrences. Reduc-
tions in sequencing cost, and the application of whole genome or
exome RNA-DNA sequencing, offer opportunities to expand the sea-
rch for clonal markers. Tumor heterogeneity may be an alternative
explanation for the 25% of paired tumors we analyzed which did
not appear clonally related: it cannot be unambiguously excluded that
clonality was masked for these tumors. Furthermore, as a relatively
rare cancer, there are limited data on UTUC-specific mutation fre-
quencies. Pertinently, recent work proposed enrichment of the FGFR3
p.R248C amino acid substitution in LS-linked UTUC, and so it is
debatable whether this shared alteration alone indicates a clonal rela-
tionship in Patient XIII. Particularly when LS patients may exhibit a
higher probability of developing multiple urinary tract tumors.16 Not-
withstanding these limitations, our observation that almost 75% of
the paired tumors were clonally related strongly suggests that seeding
of tumor cells from the upper urinary tract to the bladder represents
the most important mechanism of UCB development following RNU.
Importantly, three patients in our cohort developed multiple subse-
quent UCBs, and all tumors were clonally related to the primary
UTUC, which further supports the mechanism of seeding of tumor
cells.
5 | CONCLUSIONS
The results of our study underscore the rationale to (a) minimalize the
risk of seeding of tumor-cells during RNU; (b) carefully consider the
need for diagnostic work-up by ureterorenoscopy and biopsy, which
can dissociate cancer cells, and (c) apply perioperative intravesical
instillations with chemotherapy to kill cancer cells floating in urine.
Large-scale genomic characterization of a properly selected cohort of
UTUC and paired UCB using unbiased sequencing techniques will
overcome the aforementioned limitations and will further clarify
clonal relationships between in-patient upper and lower tract
urothelial carcinomas.
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